|
| 30577754 | Predicting tumor cell line response to drug pairs with deep learning. | BMC Bioinformatics | 2018 |
| 30577754 | Predicting tumor cell line response to drug pairs with deep learning. | BMC Bioinformatics | 2018 |
| 28446463 | The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. | Cancer Res | 2017 |
| 28446463 | The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. | Cancer Res | 2017 |
| 28158293 | Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. | PLoS One | 2017 |
| 28158293 | Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. | PLoS One | 2017 |
| 25446780 | An in silico screen links gene expression signatures to drug response in glioblastoma stem cells. | Pharmacogenomics J | 2015 |
| 25446780 | An in silico screen links gene expression signatures to drug response in glioblastoma stem cells. | Pharmacogenomics J | 2015 |
| 24885658 | Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies. | BMC Genomics | 2014 |
| 24885658 | Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies. | BMC Genomics | 2014 |
| 23856246 | The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. | Cancer Res | 2013 |
| 23856246 | The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. | Cancer Res | 2013 |
| 22305747 | Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. | Biochem Pharmacol | 2012 |
| 22305747 | Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. | Biochem Pharmacol | 2012 |
| 21636706 | Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. | Neuro Oncol | 2011 |
| 21636706 | Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. | Neuro Oncol | 2011 |
| 20375240 | Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. | Mol Endocrinol | 2010 |
| 21031001 | Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. | Nat Rev Drug Discov | 2010 |
| 20442306 | Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. | Mol Cancer Ther | 2010 |
| 20375240 | Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. | Mol Endocrinol | 2010 |
| 21031001 | Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. | Nat Rev Drug Discov | 2010 |
| 20442306 | Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. | Mol Cancer Ther | 2010 |
| 19633067 | Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. | Mol Pharmacol | 2009 |
| 19633067 | Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. | Mol Pharmacol | 2009 |
| 17520257 | Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. | Cancer Chemother Pharmacol | 2008 |
| 17520257 | Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. | Cancer Chemother Pharmacol | 2008 |
| 17245351 | Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. | Mol Ther | 2007 |
| 17942930 | Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage. | Cancer Res | 2007 |
| 17245351 | Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. | Mol Ther | 2007 |
| 17942930 | Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage. | Cancer Res | 2007 |
| 16376301 | Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. | Biochem Biophys Res Commun | 2006 |
| 16798938 | Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. | Mol Pharmacol | 2006 |
| 16546986 | Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. | Mol Cancer Ther | 2006 |
| 16397212 | Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. | Cancer Res | 2006 |
| 16489930 | Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. | Biochem J | 2006 |
| 16982767 | Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. | Cancer Res | 2006 |
| 16376301 | Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. | Biochem Biophys Res Commun | 2006 |
| 16798938 | Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. | Mol Pharmacol | 2006 |
| 16982767 | Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. | Cancer Res | 2006 |
| 16489930 | Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. | Biochem J | 2006 |
| 16397212 | Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. | Cancer Res | 2006 |
| 16546986 | Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. | Mol Cancer Ther | 2006 |
| 15748285 | HLA class I and II genotype of the NCI-60 cell lines. | J Transl Med | 2005 |
| 15655411 | Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines. | Anticancer Drugs | 2005 |
| 15748285 | HLA class I and II genotype of the NCI-60 cell lines. | J Transl Med | 2005 |
| 15655411 | Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines. | Anticancer Drugs | 2005 |
| 15120034 | Update on NCI in vitro drug screen utilities. | Eur J Cancer | 2004 |
| 15501957 | Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. | Clin Cancer Res | 2004 |
| 15541957 | Transcription profiling of gene expression in drug discovery and development: the NCI experience. | Eur J Cancer | 2004 |
| 15252146 | In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. | Mol Cancer Ther | 2004 |